Tramontana to study treatment of TBI-related attention deficits in children
Michael G. Tramontana, Ph.D., Associate Professor of Psychiatry, Neurology, and Pediatrics, was recently awarded funding from Shire Pharmaceuticals for an investigator-initiated research proposal entitled, "Treatment Outcomes with Lisdexamfetamine Dimesylate (Vyvanse) in Children with Traumatic Brain Injury-Related Attention Deficits." It will be a two-year study that will extend and refine the work of a previous clinical trial led by Dr. Tramontana that dealt primarily with adults (published in Brain Injury, 2014, 28 (11), 1461-1472).
Tramontana published in Journal of Parkinson's Disease
Michael G. Tramontana, Ph.D., Associate Professor of Psychiatry, Neurology, and Pediatrics, recently had research published in the most recent issue of the Journal of Parkinson's Disease. Tramontana was lead author on the research report "Neuropsychological Effects of Deep Brain Stimulation in Subjects with Early Stage Parkinson's Disease in a Randomized Clinical Trial." The purpose of this study was to determine the effects of DBS on neuropsychological functioning in subjects with early stage Parkinson's disease.